Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Product capable of preventing and/or treating colitis

A technology for colitis and ulcerative colitis, applied in the field of medicine, can solve problems such as unsatisfactory effect and drug side effects, and achieve the effects of prevention and/or treatment safety, reduction of expression amount, and high application prospect.

Pending Publication Date: 2020-06-05
JIANGNAN UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] At present, aminosalicylic acid (such as sulfasalazine), corticosteroids, immunosuppressants (such as azathioprine) and biological agents (such as TNF-α, ie infliximab) are mainly used clinically to alleviate the symptoms. Ulcerative colitis, however, these drugs are not as effective, and these drugs are often accompanied by serious side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Product capable of preventing and/or treating colitis
  • Product capable of preventing and/or treating colitis
  • Product capable of preventing and/or treating colitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0100] Example 1: Effects of cis9, trans11, cis15-CLNA and / or cis9, trans11, trans15-CLNA on body weight, colon tissue DAI value, colon length, colon histopathological features and colon tissue damage score in mice with ulcerative colitis

[0101] 72 C57BL6 / J male mice were randomly divided into 9 groups, 8 in each group. The 9 groups were: control group (Control), model group (DSS Model), non-modeling CLNA mixture administered with CLNA mixture samples group (CLNA Control), CLNA1 group administered with CLNA1 sample (CLNA1), CLNA2 group administered with CLNA1 sample (CLNA2), CLNA mixture group administered with CLNA mixture sample (CLNAMix), α-linolenic acid administered α -Linolenic acid group (ALA), punicic acid group administered with punicic acid (PAMix), drug group administered with mesalamine (Drug Control), among them, CLNA1 group, CLNA2 group, CLNA mixture group, α-linolenic acid group , punicic acid group and drug group are treatment groups.

[0102]The experiment ...

Embodiment 2

[0113] Example 2: cis9, trans11, cis15-CLNA and / or cis9, trans11, trans15-CLNA on the pathological characteristics of the mucus layer in the colon tissue of mice with ulcerative colitis and the biochemical indicators of the colon tissue (expression of anti-inflammatory factors, pro-inflammatory factors expression, MUC2 protein expression, tight junction protein expression, antioxidant enzyme activity, myeloperoxidase activity)

[0114] 72 C57BL6 / J male mice were randomly divided into 9 groups, 8 in each group. The 9 groups were: control group (Control), model group (DSS Model), non-modeling CLNA mixture administered with CLNA mixture samples group (CLNA Control), CLNA1 group administered with CLNA1 sample (CLNA1), CLNA2 group administered with CLNA1 sample (CLNA2), CLNA mixture group administered with CLNA mixture sample (CLNAMix), α-linolenic acid administered α -Linolenic acid group (ALA), punicic acid group administered with punicic acid (PAMix), drug group administered wit...

Embodiment 3

[0125] Example 3: Effects of cis9, trans11, cis15-CLNA and / or cis9, trans11, trans15-CLNA on the types of fatty acids and the contents of each fatty acid in the blood, liver, and colon contents of mice with ulcerative colitis

[0126] 72 C57BL6 / J male mice were randomly divided into 9 groups, 8 in each group. The 9 groups were: control group (Control), model group (DSS Model), non-modeling CLNA mixture administered with CLNA mixture samples group (CLNA Control), CLNA1 group administered with CLNA1 sample (CLNA1), CLNA2 group administered with CLNA1 sample (CLNA2), CLNA mixture group administered with CLNA mixture sample (CLNAMix), α-linolenic acid administered α -Linolenic acid group (ALA), punicic acid group administered with punicic acid (PAMix), drug group administered with mesalamine (Drug Control), among them, CLNA1 group, CLNA2 group, CLNA mixture group, α-linolenic acid group , punicic acid group and drug group are treatment groups.

[0127] The experiment lasted for t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a product capable of preventing and / or treating colitis and belongs to the technical field of medicines. The product can relieve UC ((ulcerative colitis), specifically, c9, t11, c15-CLNA and / or c9, t11 and t15-CLNA can relieve sudden weight loss of mice with UC, reduce DAI value, injury score and expression of inflammatory cytokines of colon tissues of the mice with UC, increase expression of proinflammatory factors, MUC2 protein and tight junction protein in the colon tissues of the mice with UC, increase the activity of antioxidant enzyme in the colon tissues of themice with UC and reduce the expression of myeloperoxidase in the colon tissues of the mice with UC.

Description

technical field [0001] The invention relates to a product capable of preventing and / or treating colitis, and belongs to the technical field of medicine. Background technique [0002] Ulcerative colitis (UC) is a chronic non-specific inflammatory disease of the colon and rectum whose etiology and pathogenesis are still unclear. Ulcer-based, mostly involving the rectum and sigmoid colon, sometimes throughout the entire colon), the acute fulminant type has a high mortality rate, the chronic persistent type has a high rate of canceration, and is prone to recurrent attacks. At present, there is no specific drug for treating ulcerative colitis. Therefore, ulcerative colitis is listed as one of the modern refractory diseases by the World Health Organization. [0003] Ulcerative colitis can occur at any age, but it is more common in 20 to 40 years old, and can also be seen in children or the elderly. In the past, ulcerative colitis mainly occurred in European and American countrie...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/202A61K35/747A61P1/00A61P1/04A23L33/12
CPCA61K31/202A61K35/747A61P1/00A61P1/04A23L33/12A23V2002/00A23V2400/169A23V2200/30A23V2250/1874
Inventor 陈海琴杨波任青赵建新张灏陈卫
Owner JIANGNAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com